CVC DIF emphasizes the importance of a systematic approach to value creation in the infrastructure sector, as highlighted by Angela Roshier, the Head of Value Creation. This method is essential for achieving superior performance throughout various market cycles.

In recent news from the CVC network, several significant developments have occurred. On February 20, 2025, CVC DIF discussed strategies for uncovering hidden potential in investments. The following day, CVC Credit announced the pricing of Cordatus XXXIV, marking its first new issue CLO for 2025.

A full-year activity update was released on February 14, 2025, providing insights into CVC's performance and initiatives. On February 12, it was reported that Torrent Group is set to acquire a majority stake in the Gujarat Titans, indicating ongoing investment activity in sports and entertainment.

CVC Credit also shared its perspectives on attractive opportunities in global credit for Q4 2024 on February 10, 2025. This reflects the firm's commitment to identifying promising investment avenues in a dynamic market.

On February 7, CVC Credit priced its first CLO transaction of the year, further demonstrating its active role in the credit market. Additionally, on February 6, CVC Credit supported Eurazeo and Oakley in their acquisition of I-TRACING, showcasing collaboration with other investment firms.

CVC DIF made headlines on February 6 as well, agreeing to sell a portfolio of over 1GW of renewable energy projects to Potentia Energy. This transaction underscores CVC's focus on sustainable investments.

Earlier in January, CVC Funds finalized the sale of OANDA to FTMO on January 3, 2025. This move reflects CVC's ongoing strategy to optimize its portfolio.

On January 27, PureHealth announced its agreement to acquire a majority stake in Hellenic Healthcare Group from CVC-managed funds in a substantial EUR 2.2 billion transaction. This acquisition highlights CVC's involvement in the healthcare sector.

Lastly, on January 24, CVC Credit provided debt facilities for the joint acquisition of Immedica Pharma by KKR and Impilo, further illustrating its active participation in financing significant deals.

Overall, CVC's recent activities demonstrate a robust engagement in various sectors, including infrastructure, healthcare, and credit markets, while maintaining a focus on value creation and strategic partnerships.